Inclusion Body Myositis Market By Structural Feature 2021 | IndustryARC
  • 1-614-588-8538 (Ext: 101)
  • US Toll Free

Inclusion Body Myositis Market
Inclusion Body Myositis Market: By Structural Feature (Cytoplasmic Vacuolation, Inflammatory Infiltrate & Tubo-Filamentous) & By Test Type(Full blood count, Calcium & Phosphate, Nerve conduction, Muscle Biopsy, Electron Microscopy, Others)-Forecast (2016-2021)
Report Code : HCR 0202
Updated Date: 25 February, 2016  

  • Report Description
  • Table of Contents
  • Customization Options
Inclusion body myositis or IBM as it is commonly referred to, is a muscle disorder, which presents itself with age. As IBM is a disorder and not a disease, there is no cure as such and is inevitable for aged individuals. The onset of this disorder affects an individual’s normal motor functions as it attacks the individual’s muscles, tendons and ligaments. As the disorder strikes an individual at the internal level, it can often be missed. There have been numerous cases of the disorder being misdiagnosed, which often leads to complications in the long term. The disorder normally presents itself in individuals over the age of 60, however, there have been situations where the disorder has been affecting individuals as young as 40. This has been noticed over the last decade and can be attributed to the lifestyle being in play these days. Sedentary lifestyles, no proper sleep pattern, improper diet and so on often lead to muscle fatigue which eventually is a precursor for IBM in the long run and hence, affects younger individuals as well.

There is no specific test which can identify IBM in an individual, however, a combination of tests such as Full blood count, Calcium and Phosphate, Creatine Kinase, Erythrocyte Sedimentation Rate and so on will be a good indicator of whether the disorder has set in or not. There are however a number of therapies which have helped in slowing down IBM. This however is something, which is not found to be true across the board for all individuals, and results tend to vary. As such, clinical trials are still ongoing by numerous companies, but nothing has been confirmed as of yet.

In terms of which regions are affected the most by this, North America and Europe are affected the most as on date. A number of reasons could be responsible for this, some of which include the lifestyle being led as well as the climatic conditions where the cold could aid the early onset of this disorder. It is also for this reason that there is a high demand for numerous therapies in these regions for IBM.

Inclusion Body Myositis Market

The Inclusion body myositis Market can be segmented as
  • on the basis of structural feature
    • Cytoplasmic Vacuolation, Inflammatory Infiltrate and Tubo-Filamentous
  • In terms of test type 
    • Full blood count, Calcium and Phosphate, Creatine Kinase, Erythrocyte Sedimentation Rate, and Fasting Glucose, Nerve conduction, Electromyography, Muscle Biopsy and Electron Microscopy
  • By Geography 
    • North America, South America, APAC, Europe, Middle East and Africa

Following are just a few of the companies that are operating in the Inclusion body myositis Market.
  • Gradalis, Inc
  • New Zealand Pharmaceuticals Ltd
  • Nobelpharma Co
  • Novartis AG.
1. Inclusion body myositis– Market Overview
2. Executive Summary
3. Inclusion body myositis– Market Landscape

   3.1. Market Share Analysis
   3.2. Comparative Analysis
      3.2.1. Product Benchmarking
      3.2.2. End User Profiling
      3.2.3. Top 5 Financials Analysis
4. Inclusion body myositis– Market Forces
   4.1. Market Drivers
   4.2. Market Constraints
   4.3. Market Challenges
   4.4. Attractiveness of the Inclusion body myositis Market
      4.4.1. Power of Suppliers
      4.4.2. Power of Customers
      4.4.3. Threat of New Entrants
      4.4.4. Threat of Substitution
      4.4.5. Degree of Competition
5. Inclusion body myositis Market– Strategic Analysis
   5.1. Value Chain Analysis
   5.2. Pricing Analysis
   5.3. Opportunities Analysis
   5.4. Product/Market Life Cycle Analysis
   5.5. Suppliers and Distributors
6. Inclusion body myositis Market– By Structural Feature:
   6.1. Cytoplasmic Vacuolation
   6.2. Inflammatory Infiltrate
   6.3. Tubo-Filamentous 
7. Inclusion body myositis Market– By Test Type: 
   7.1. Full blood count
   7.2. Calcium and Phosphate
   7.3. Creatine Kinase
   7.4. Erythrocyte Sedimentation Rate
   7.5. Fasting Glucose
   7.6. Nerve conduction
   7.7. Electromyography
   7.8. Muscle Biopsy
   7.9. Electron Microscopy
8. Inclusion body myositis Market– By Geography:
   8.1. Introduction
   8.2. Global Study
   8.3. Americas
      8.3.1. North America
      8.3.2. Brazil
      8.3.3. Argentina
      8.3.4. Others
   8.4. Europe
      8.4.1. U.K.
      8.4.2. France
      8.4.3. Germany
      8.4.4. Others
   8.5. APAC
      8.5.1. China
      8.5.2. Japan
      8.5.3. India
      8.5.4. Others
   8.6. ROW
9. Inclusion body myositis Market Entropy
   9.1. New Product Launches
   9.2. M&As, Collaborations, JVs and Partnerships
10. Company Profiles
   10.1. Gradalis, Inc.
   10.2. New Zealand Pharmaceuticals Ltd.
   10.3. Nobelpharma Co
   10.4. Novartis AG
*More than 40 Companies are profiled in this Research Report, Complete List available on Request*
"*Financials would be provided on a best efforts basis for private companies"
11. Appendix

   11.1. Abbreviations
   11.2. Sources
   11.3. Research Methodology
   11.4. Bibliography
   11.5. Compilation of Expert Insights
   11.6. Disclaimer
Please select Licence
Single User Licence:
US $4250
Corporate User Licence:
US $6250
Related Reports